Citations (69)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Aslihan Uzun, Fatime Nilufer Yalcindag, Sibel Demirel, Figen Batýoðlu & Emin Ozmert. (2017) Evaluation of Aqueous Flare Levels Following Intravitreal Ranibizumab Injection for Neovascular Age-related Macular Degeneration. Ocular Immunology and Inflammation 25:2, pages 229-232.
Read now
Read now
Dongqing Yuan, Hong Shen, Songtao Yuan, Xiaoyi Liu, Xin Xia, Ping Xie, Weiguang Li, Jialiang Hu, Qinghuai Liu & Hanmei Xu. (2014) Pharmacokinetics of HM-3 After Intravitreal Administration in Mice. Current Eye Research 39:8, pages 837-844.
Read now
Read now
Articles from other publishers (67)
Paulo Eduardo Stanga, Francisco Javier Valentín-Bravo, Sebastian Eduardo Francis Stanga, Ursula Inge Reinstein, Salvador Pastor-Idoate & Susan M. Downes. (2023) Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic. Eye.
Crossref
Crossref
Azam Habibi, Zeinab Zarei-Behjani, Kimia Falamarzi, Mahdi Malekpour, Fatemeh Ebrahimi, Masood Soleimani, Mahmood Nejabat, Amir Khosravi, Zahra Moayedfard, Sara Pakbaz, Niloofar Dehdari Ebrahimi & Negar Azarpira. (2023) Extracellular vesicles as a new horizon in the diagnosis and treatment of inflammatory eye diseases: A narrative review of the literature. Frontiers in Immunology 14.
Crossref
Crossref
Xiao Zhang, Lei Chen, Oswaldo L. Bracco, Soko Setoguchi, Wei Zhou & Mehmet Burcu. (2021) Regulator‐Requested Non‐Interventional Postauthorization Safety and Effectiveness Studies for Oncology Drugs: A Systematic Review. Clinical Pharmacology & Therapeutics 111:1, pages 155-167.
Crossref
Crossref
Görkem Giray. (2021) A software engineering perspective on engineering machine learning systems: State of the art and challenges. Journal of Systems and Software 180, pages 111031.
Crossref
Crossref
Richard F. Spaide. (2021) ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR DOSING AND EXPECTED ACUITY OUTCOME AT 1 YEAR. Retina 41:6, pages 1153-1163.
Crossref
Crossref
Mei-mei Liu, Xiu-hui Chen, Xiu-min Lu, Fang-fang Wang, Chao Wang, Yu Liu, Pei-ling Li, Bo-tao Du, Sha Liang, Pi-dong Gong & Yu-xin Wang. (2021) Variations in the Profiles of Vascular-Related Factors Among Different Sub-Types of Polycystic Ovarian Syndrome in Northern China. Frontiers in Endocrinology 11.
Crossref
Crossref
Anja Nitzsche, Riikka Pietilä, Dominic T Love, Chiara Testini, Takeshi Ninchoji, Ross O Smith, Elisabet Ekvärn, Jimmy Larsson, Francis P Roche, Isabel Egaña, Suvi Jauhiainen, Philipp Berger, Lena Claesson‐Welsh & Mats Hellström. (2020) Paladin is a phosphoinositide phosphatase regulating endosomal VEGFR2 signalling and angiogenesis. EMBO reports 22:2.
Crossref
Crossref
Peter Walter & Steffen Rex. 2021. Chirurgie für Anästhesisten. Chirurgie für Anästhesisten
105
116
.
Catherine Ménard, Ariel M. Wilson, Agnieszka Dejda, Khalil Miloudi, François Binet, Sergio Crespo-Garcia, Célia Parinot, Frédérique Pilon, Rachel Juneau, Elisabeth MMA Andriessen, Gaëlle Mawambo, John Paul SanGiovanni, Vincent De Guire & Przemyslaw Sapieha. (2020) miR-106b suppresses pathological retinal angiogenesis. Aging 12:24, pages 24836-24852.
Crossref
Crossref
Zaid Shalchi, Omar Mahroo, Catey Bunce & Danny Mitry. (2020) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database of Systematic Reviews 2020:7.
Crossref
Crossref
Soumaya Hachana, Olivier Fontaine, Przemyslaw Sapieha, Mark Lesk, Réjean Couture & Elvire Vaucher. (2020)
The effects of anti‐VEGF and kinin B
1
receptor blockade on retinal inflammation in laser‐induced choroidal neovascularization
. British Journal of Pharmacology 177:9, pages 1949-1966.
Crossref
Crossref
Fenghua Wang, Yuanzhi Yuan, Ling Wang, Xiaofeng Ye, Jingke Zhao, Mengxi Shen, Qi Zhang, Ding Xu, Guoyou Qin, Wei Zhang, Fei Yuan, Qing Chang, Peiquan Zhao, Fang Wang & Xiaodong Sun. (2019) One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial. Journal of Ophthalmology 2019, pages 1-6.
Crossref
Crossref
Michèle Augsburger, Gian-Marco Sarra & Pascal Imesch. (2019) Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study. Graefe's Archive for Clinical and Experimental Ophthalmology 257:9, pages 1889-1895.
Crossref
Crossref
Andy Wai Kan Yeung, Mohamed M. Abdel-Daim, Abdelrahman Ibrahim Abushouk & Kazuaki Kadonosono. (2019) A literature analysis on anti-vascular endothelial growth factor therapy (anti-VEGF) using a bibliometric approach. Naunyn-Schmiedeberg's Archives of Pharmacology 392:4, pages 393-403.
Crossref
Crossref
Sharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik & Barbara S Hawkins. (2019) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2019:3.
Crossref
Crossref
A. Arranz-Romera, B.M. Davis, I. Bravo-Osuna, S. Esteban-Pérez, I.T. Molina-Martínez, E. Shamsher, N. Ravindran, L. Guo, M.F. Cordeiro & R. Herrero-Vanrell. (2019) Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. Journal of Controlled Release 297, pages 26-38.
Crossref
Crossref
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn & Lucas M. Bachmann. (2018) Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context. BMC Ophthalmology 18:1.
Crossref
Crossref
Laura E. Downie, Eve Makrai, Yokim Bonggotgetsakul, Lucy J. Dirito, Kresimir Kristo, Minh-An N. Pham, Mina You, Karin Verspoor & Michael J. Pianta. (2018) Appraising the Quality of Systematic Reviews for Age-Related Macular Degeneration Interventions. JAMA Ophthalmology 136:9, pages 1051.
Crossref
Crossref
Mariana Di Pietro, Natalia Pascuali, Fernanda Parborell & Dalhia Abramovich. (2018) Ovarian angiogenesis in polycystic ovary syndrome. Reproduction 155:5, pages R199-R209.
Crossref
Crossref
Rajkumar PatilHaishan WangNajam A. SharifAlok Mitra. (2018) Aquaporins: Novel Targets for Age-Related Ocular Disorders. Journal of Ocular Pharmacology and Therapeutics 34:1-2, pages 177-187.
Crossref
Crossref
Divya Ail & Muriel Perron. (2017) Retinal Degeneration and Regeneration—Lessons From Fishes and Amphibians. Current Pathobiology Reports 5:1, pages 67-78.
Crossref
Crossref
Shaker A. Mousa & Paul J. Davis. 2017. Anti-Angiogenesis Strategies in Cancer Therapeutics. Anti-Angiogenesis Strategies in Cancer Therapeutics
1
19
.
Rajkumar Patil, Ching-Yu Cheng, Chui Ming Gemmy Cheung & Tien Yin Wong. 2017. Advances in Vision Research, Volume I. Advances in Vision Research, Volume I
497
507
.
Rajkumar Patil, Chee Wai Wong, Fabio Michelet, Kelvin Teo, Daniel Ting, Andrew Tsai, Chui Ming Gemmy Cheung & Tien Yin Wong. 2017. Biochemical Basis and Therapeutic Implications of Angiogenesis. Biochemical Basis and Therapeutic Implications of Angiogenesis
259
297
.
Emily D. Cole, Daniela Ferrara, Eduardo A. Novais, Ricardo N. Louzada & Nadia K. Waheed. (2016) CLINICAL TRIAL ENDPOINTS FOR OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina 36:Supplement 1, pages S83-S92.
Crossref
Crossref
Yao Tong, Ya-Li Zhou, Yi-Xiao Wang, Pei-Quan Zhao & Zhao-Yang Wang. (2016) Retinal pigment epithelium cell-derived exosomes: Possible relevance to CNV in wet-age related macular degeneration. Medical Hypotheses 97, pages 98-101.
Crossref
Crossref
Hemangi R. Panchmatia, Karen M. Clements, Erin Hulbert, Marianne Eriksson, Kim Wittrup-Jensen, Jonas Nilsson & Milton C. Weinstein. (2016) Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden. Acta Ophthalmologica 94:5, pages 441-448.
Crossref
Crossref
Bobak Bahrami, Meidong Zhu, Thomas Hong & Andrew Chang. (2016) Diabetic macular oedema: pathophysiology, management challenges and treatment resistance. Diabetologia 59:8, pages 1594-1608.
Crossref
Crossref
Kristina Lindsley, Tianjing Li, Elizabeth Ssemanda, Gianni Virgili & Kay Dickersin. (2016) Interventions for Age-Related Macular Degeneration. Ophthalmology 123:4, pages 884-897.
Crossref
Crossref
Salman Sarwar, Elizabeth Clearfield, Mohamed Kamel Soliman, Mohammad Ali Sadiq, Andrew J Baldwin, Mostafa Hanout, Aniruddha Agarwal, Yasir J Sepah, Diana V Do & Quan Dong Nguyen. (2016) Aflibercept for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews 2016:2.
Crossref
Crossref
Eduardo A. Novais, Emmerson Badaró, Flavio E. Hirai, Felipe Abdo Jorge, Paula Leal, Michel Eid Farah & Eduardo B. Rodrigues. (2016) Daily Optical Coherence Tomography Examinations after First Antivascular Endothelial Growth Factor Injections: An Interventional Case Series. Journal of Ophthalmology 2016, pages 1-6.
Crossref
Crossref
H. Büning & U. T. Hacker. 2016. Protein Targeting Compounds. Protein Targeting Compounds
261
285
.
Dujon Fuzzard, Robyn H. Guymer & Robert P. Finger. 2016. Anti-Angiogenic Therapy in Ophthalmology. Anti-Angiogenic Therapy in Ophthalmology
31
65
.
Martin K. Schmid, Oliver Reich, Livia Faes, Sophie C. Boehni, Mario Bittner, Jeremy P. Howell, Michael A. Thiel, Andri Signorell & Lucas M. Bachmann. (2015) Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life. PLOS ONE 10:8, pages e0135050.
Crossref
Crossref
Ahmed Ebraheem Al Subaie, Hazem Eimar, Mohamed-Nur Abdallah, Robert Durand, Jocelyne Feine, Faleh Tamimi & Elham Emami. (2015) Anti-VEGFs hinder bone healing and implant osseointegration in rat tibiae. Journal of Clinical Periodontology 42:7, pages 688-696.
Crossref
Crossref
Dan-Dan Wang, Pei-Ying Xu, Tian-Yu Wang, Xiao-Xia Chen & Qing Peng. (2015) Observation on health quality of life before and after the injection of antiangiogenic drug in vitreous cavity to patients with wet age-related macular degeneration. Chinese Nursing Research 2:1, pages 27-30.
Crossref
Crossref
Martin K Schmid, Lucas M Bachmann, Livia Fäs, Alfons G Kessels, Oliver M Job & Michael A Thiel. (2015) Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. British Journal of Ophthalmology 99:2, pages 141-146.
Crossref
Crossref
Bianka Sobolewska, Cornelia Grimmel, Aikaterini Gatsiou, Kateryna Sopova, Judith Klein, Tilo Biedermann, Konstantinos Stellos & Focke Ziemssen. (2015) Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile. Ophthalmologica 234:4, pages 195-210.
Crossref
Crossref
James G. Carter, Melissa V. R. Gammons, Gopinath Damodaran, Amanda J. Churchill, Steven J. Harper & David O. Bates. (2014) The carboxyl terminus of VEGF-A is a potential target for anti-angiogenic therapy. Angiogenesis 18:1, pages 23-30.
Crossref
Crossref
H. Büning & U. T. Hacker. 2015. Protein Targeting Compounds. Protein Targeting Compounds
261
285
.
A. I. Markowska, Z. Cao & N. Panjwani. (2014) Glycobiology of ocular angiogenesis. Glycobiology 24:12, pages 1275-1282.
Crossref
Crossref
Davin Johnson, Lisa Jagan, Ayaz Kurji, Klaudia Jumaa & Sanjay Sharma. (2014) Emergency department visits after intravitreal bevacizumab and ranibizumab injections in diabetic patients. Canadian Journal of Ophthalmology 49:6, pages e146-e148.
Crossref
Crossref
Salman Sarwar, Jose R Maya, Mostafa Hanout, Yasir J Sepah, Diana V Do & Quan Dong Nguyen. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Wei Wang & Xiulan Zhang. (2014) Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis. PLoS ONE 9:10, pages e109744.
Crossref
Crossref
Sharon D Solomon, Kristina Lindsley, Satyanarayana S Vedula, Magdalena G Krzystolik & Barbara S Hawkins. (2014) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews.
Crossref
Crossref
H. A. Dakin, S. Wordsworth, C. A. Rogers, G. Abangma, J. Raftery, S. P. Harding, A. J. Lotery, S. M. Downes, U. Chakravarthy & B. C. Reeves. (2014) Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open 4:7, pages e005094-e005094.
Crossref
Crossref
Szilárd Kiss, Ying Liu, Joseph Brown, Nancy M. Holekamp, Arghavan Almony, Joanna Campbell & Jonathan W. Kowalski. (2014) Clinical Monitoring of Patients With Age-Related Macular Degeneration Treated With Intravitreal Bevacizumab or Ranibizumab. Ophthalmic Surgery, Lasers and Imaging Retina 45:4, pages 285-291.
Crossref
Crossref
Min-Yen Hsu, Chung-Yao Yang, Wen-Hsin Hsu, Keng-Hung Lin, Chun-Yuan Wang, Ying-Cheng Shen, Yu-Chen Chen, Siu-Fung Chau, Hin-Yeung Tsai & Chao-Min Cheng. (2014) Monitoring the VEGF level in aqueous humor of patients with ophthalmologically relevant diseases via ultrahigh sensitive paper-based ELISA. Biomaterials 35:12, pages 3729-3735.
Crossref
Crossref
Nancy M. Holekamp, Ying Liu, Wei-Shi Yeh, Yifeng Chia, Szilárd Kiss, Arghavan Almony & Jonathan W. Kowalski. (2014) Clinical Utilization of Anti-VEGF Agents and Disease Monitoring in Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology 157:4, pages 825-833.e1.
Crossref
Crossref
Benjamin M. Davis, Eduardo M. Normando, Li Guo, Lisa A. Turner, Shereen Nizari, Paul O'Shea, Stephen E. Moss, Satyanarayana Somavarapu & M. Francesca Cordeiro. (2014) Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5-associated Liposomes. Small 10:8, pages 1575-1584.
Crossref
Crossref
Nicole H. Siegel & Manju L. Subramanian. 2014. Predictive ADMET. Predictive ADMET
569
581
.
Andrew Payne, Simon Kaja, Yuliya Naumchuk, Nancy Kunjukunju & Peter Koulen. (2014) Antioxidant Drug Therapy Approaches for Neuroprotection in Chronic Diseases of the Retina. International Journal of Molecular Sciences 15:2, pages 1865-1886.
Crossref
Crossref
Paolo Lanzetta, Paul Mitchell, Sebastian Wolf & Daniele Veritti. (2013) Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. British Journal of Ophthalmology 97:12, pages 1497-1507.
Crossref
Crossref
Andreas Pollreisz, Taras Afonyushkin, Olga V. Oskolkova, Florian Gruber, Valery N. Bochkov & Ursula Schmidt-Erfurth. (2013) Retinal pigment epithelium cells produce VEGF in response to oxidized phospholipids through mechanisms involving ATF4 and protein kinase CK2. Experimental Eye Research 116, pages 177-184.
Crossref
Crossref
Usha Chakravarthy, Simon P Harding, Chris A Rogers, Susan M Downes, Andrew J Lotery, Lucy A Culliford & Barnaby C Reeves. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. The Lancet 382:9900, pages 1258-1267.
Crossref
Crossref
Stefan J. R. de Geus, Martine J. Jager, Gré P. M. Luyten & Greet Dijkman. (2013) Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab. Acta Ophthalmologica 91:5, pages e411-e413.
Crossref
Crossref
Dong Hyun JoJin Hyoung KimTae Geol LeeJeong Hun Kim. (2013) Nanoparticles in the Treatment of Angiogenesis-Related Blindness. Journal of Ocular Pharmacology and Therapeutics 29:2, pages 135-142.
Crossref
Crossref
Danny Mitry, Catey Bunce & David Charteris. (2013) Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Shaker A. Mousa. 2013. Angiogenesis Modulations in Health and Disease. Angiogenesis Modulations in Health and Disease
95
106
.
Michele Rinaldi, Flavia Chiosi, Roberto dell'Omo, Mario R. Romano, Francesco Parmeggiani, Francesco Semeraro, Rodolfo Mastropasqua & Ciro Costagliola. (2012) Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study. British Journal of Clinical Pharmacology 74:6, pages 940-946.
Crossref
Crossref
Bärbel RohrerBeth CoughlinMausumi Bandyopadhyay & V. Michael Holers. (2012) Systemic Human CR2-Targeted Complement Alternative Pathway Inhibitor Ameliorates Mouse Laser-Induced Choroidal Neovascularization. Journal of Ocular Pharmacology and Therapeutics 28:4, pages 402-409.
Crossref
Crossref
Dalhia Abramovich, Griselda Irusta, Diana Bas, Natalia Isabel Cataldi, Fernanda Parborell & Marta Tesone. (2012) Angiopoietins/TIE2 System and VEGF Are Involved in Ovarian Function in a DHEA Rat Model of Polycystic Ovary Syndrome. Endocrinology 153:7, pages 3446-3456.
Crossref
Crossref
James Harrison, Carole A. Bartlett, Gary Cowin, Philip K. Nicholls, Cameron W. Evans, Tristan D. Clemons, Bogdan Zdyrko, Igor A. Luzinov, Alan R. Harvey, K. Swaminathan Iyer, Sarah A. Dunlop & Melinda Fitzgerald. (2012) In vivo Imaging and Biodistribution of Multimodal Polymeric Nanoparticles Delivered to the Optic Nerve. Small 8:10, pages 1579-1589.
Crossref
Crossref
Shusheng WangKyle M KosterYuguang HeQinbo Zhou. (2012) miRNAs as potential therapeutic targets for age-related macular degeneration. Future Medicinal Chemistry 4:3, pages 277-287.
Crossref
Crossref
Courtney L. Kraus & Susan M. Culican. (2012) Use of Biologic Agents in Ocular Manifestations of Rheumatic Disease. International Journal of Rheumatology 2012, pages 1-6.
Crossref
Crossref
Anna‐Lena Hård & Ann Hellström. (2011) On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. Acta Paediatrica 100:12, pages 1523-1527.
Crossref
Crossref
Focke Ziemssen & Bianka Sobolewska. (2011) Therapeutic Efficacy of Bevacizumab for Age-Related Macular Degeneration. Drugs & Aging 28:11, pages 853-865.
Crossref
Crossref